<DOC>
	<DOCNO>NCT01610713</DOCNO>
	<brief_summary>An open-label extension study patient multiple sclerosis receive GW-1000-02 [ name Sativex® Canada also name Sativex® Oromucosal Spray ] four week open-label manner .</brief_summary>
	<brief_title>An Study Investigate Efficacy Delta-9-tetrahydrocannabinol ( THC ) Cannabidiol ( CBD ) Multiple Sclerosis</brief_title>
	<detailed_description>Subjects take part GWMS0001 Part A invited continue receive GW-1000-02 four-week open-label part study . Subjects receive open-label cannabinoid extract ( GW-1000-02 ) four week , either without peppermint flavouring , accord study centre . Subjects complete study could choose continue receive GW-1000-02 enter long-term safety extension follow-on study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Aged least 18 year . Multiple Sclerosis type . Stable Multiple Sclerosis symptomatology four week study entry . Symptoms require severity ( &gt; 50 mm 100 mm Visual Analogue Scale severity scale ) least one specify impairment category ; spasticity , muscle spasm , disturbed bladder control , neuropathic pain , limb tremor . A stable medication regime four week study entry . Willing abstain cannabis cannabinoids least seven day study entry , study . Agreed either use effective contraception study three month thereafter , surgically sterilise , female , postmenopausal . Clinically acceptable laboratory result prestudy screen . Willing able undertake comply study requirement . Willing able read , consider understand subject information consent form give write informed consent . Subjects unable read sign document procedure treat detailed Declaration Helsinki . Willing general practitioner , consultant appropriate , inform study participation . Willing name notify Home Office participation study . Known strongly suspect abuse drug , include alcohol . Not prepared abstain cannabis cannabinoids study . Current past addiction cannabis . Known suspected adverse reaction cannabinoids cause psychosis severe psychiatric illness . History type schizophrenia , psychotic illness , significant psychiatric illness personality disorder depression associate chronic illness . Received drug contain levodopa ( Sinemet® , Sinemet plus® , Levodopa® , Ldopa® , Madopar® , Benserazide® ) . Serious cardiovascular disorder include angina , uncontrolled hypertension , uncontrolled symptomatic cardiac arrhythmia . Significant renal hepatic impairment show medical history indicate laboratory result . History epilepsy . Terminal illness condition placebo medication would inappropriate . Pregnant , lactate risk pregnancy . Participated clinical research study 12 week study entry . Planned hospital admission study entry Visit 6 . Planned travel outside UK study entry Visit 6 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>